Editorial: Photobiomodulation and phototherapy in skin diseases

This Research Topic was designed to foster insights into advances in the mechanisms and application of photobiomodulation and phototherapy for skin diseases in order to provoke further translational research in this area. We eventually ended up with two original research papers, two brief research reports, one clinical trial and one case report.The first research report was by Marchegiani and colleagues who investigated the use of fluorescent light energy (FLE) to treat canine superficial bacterial folliculitis (https://www.frontiersin.org/articles/10.3389/fvets.2023.1155105/full). Superficial bacterial folliculitis (SBF) is a bacterial infection that is confined within the hair follicles, without invasion of the dermis [1]. Staphylococcus pseudintermedius is a normal commensal species in canine skin and is the main cause of SBF [2]. Topical and systemic antibiotics are the most often employed treatments for canine SBF, but antibiotic resistance is a growing problem. FLE consisted of applying a layer of yellow gel containing fluorescent dyes to the affected skin and then irradiating with blue light (440-460 nm, 55 -129 mW/cm2) for 2 min. Six dogs received FLE once, six dogs twice, while eight dogs received oral antibiotics until complete healing was observed. FLE was able to significantly reduce the time needed for clinical resolution compared to antibiotics alone, improving the owners' compliance and welfare of the dogs.The second research report was by Hu and co-workers who carried out a retrospective evaluation of hemoporfin-mediated photodynamic therapy (HM-PDT) for port-wine stains (https://www.frontiersin.org/articles/10.3389/fmed.2023.1170520/full). Hemoporfin is hematoporphyrin monomethyl ether and has been shown to be effective in destroying the abnormal vasculature after IV administration and activation by green light [3]. Because PDT can be very painful, general anesthesia is sometimes employed in patients who would otherwise be unable to tolerate the procedure. This paper asked the question whether the use of general anesthesia affected the outcome of the PDT on the port wine stain. They looked at 207 patients treated with HM-PDT of whom 137 received a general anesthetic, while 69 did not. The treatment efficacy was significantly higher in the general anesthetic group than in the nonanesthetic group (76.81 vs. 56.52%, p < 0.05). Purpura lasted longer in the anesthetic group, but the other side effects were similar between the two groups.Solar lentigenes are disfiguring brown spots on the face, which are often treated with a picosecond pulsed 755-nm alexandrite laser especially in Asian skin types [4]. In a brief research report, Liu and colleagues asked whether video education could improve the process of obtaining informed consent for this procedure (https://www.frontiersin.org/articles/10.3389/fmed.2023.1158842/full). In a retrospective study they compared 56 patients who received additional video education, while 50 patients underwent traditional informed consent. More correct answers were given by older and less educated patients who received video education, while the video group also reported improved patient satisfaction compared to the traditional group.The second brief research report by Yu et al described a prospective randomized half-body study comparing 308 nm LED light vs. 308 nm excimer laser for treating localized psoriasis (https://www.frontiersin.org/articles/10.3389/fmed.2023.1275912/full). The 308 nm excimer laser has been used to treat psoriasis since 2000 [5], but the device is expensive and bulky. Ten patients with symmetrical skin lesions of mild-to-moderate psoriasis completed a prospective, randomized, split sided clinical trial. The target lesions were randomly treated with either LED light or excimer laser twice a week for 12 weeks. The responses as evaluated by the local psoriasis severity index scores and dermoscopic features were similar on both sides of the body. Because 308 nm LEDS are more portable and cost-effective compared to the excimer laser, they should be considered in the future for psoriasis treatment.The clinical trial was conducted by Dai et al who investigated the laser treatment of atrophic acne scars in Asian patients (https://www.frontiersin.org/articles/10.3389/fmed.2023.1248831/full). Atrophic acne scars are a disfiguring and distressing complication of acne which may affect up to 95% of patients [6]. Dai et al carried out a 20-week prospective, randomized, split-face, controlled pilot study comparing 1064-nm Nd:YAG picosecond laser using a fractional micro-lens array (P-MLA) versus an ablative fractional 2940-nm Er:YAG laser (AF-Er) in 31 patients. The Echelle d'Evaluation Clinique des Cicatrices d'acne (ECCA) grading scale, Investigator Global Assessment (IGA) scores, patient satisfaction, and VISIA analysis were employed to evaluate the improvement in the scars. Both lasers produced equivalent improvements in ECCA and IGA scores, but patient satisfaction was higher for the AF-Er-treated side. VISIA analysis revealed the pore and skin texture was similar for both devices. No serious side effects were reported, but the P-MLA side had less pain and shorter duration of crust shedding and edema.The final case report by Ping and colleagues described the treatment of a patient with acne vulgaris using a combination of 5-aminolaevulinic acid mediated photodynamic therapy and the monoclonal antibody adalimumab (https://www.frontiersin.org/articles/10.3389/fmed.2023.1187186/full). Adalimumab (also known as Humira) binds to and inactivates the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-a) [7]. It has used to treat many chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis [8], but has not often been used as a monotherapy for acne [9]. ALA-PDT is often used for treating recalcitrant acne due to its ability to reduce sebum secretion while at the same time killing the Cutibacterium acnes bacteria, which colonize the sebaceous glands [10]. The patient who suffered from severe acne and had previously failed other therapies, was treated with ALA PDT once a week for 3 weeks and three injection of Humira once every 2 weeks. The active acne lesions then resolved leaving some residual scars.